Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial of CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With Donor-specific Antibodies

NCT07451236 is registered in ClinicalTrials.gov with Chang Yingjun as lead sponsor.

NCT NCT07451236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07451236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial of CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With Donor-specific Antibodies
Lead sponsor
Chang Yingjun
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
March 18, 2026
Completion date
December 31, 2027
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

transplantation candidates with hematological diseases